Richard Francis

Richard Francis joined in September 2021 as Head of CMC, bringing more than 35 years of experience in the development, manufacturing, regulatory approval and commercialization of many biopharmaceutical products including Cablivi®, Orthoclone OKT3®, Remicade®, and ReoPro®.